Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma

Documenti analoghi

• Therapeutic Effect Of First-Line EGFR-TKIs Combined With Concurrent Cranial Radiotherapy On NSCLC Patients With EGFR Activating Mutation And Brain Metastasis: A Retrospective Study
  di: An, Ning, et al.
  Pubblicazione: (2019)
• Risk of brain metastasis reduced after erlotinib treatment in advanced pulmonary adenocarcinoma patients with sensitive EGFR mutation
  di: Liu, Jing, et al.
  Pubblicazione: (2016)
• Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
  di: Wen, Miaomiao, et al.
  Pubblicazione: (2018)
• Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis
  di: Chen, Yanxin, et al.
  Pubblicazione: (2019)
• Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
  di: Wei, Zhigang, et al.
  Pubblicazione: (2017)